Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00120718 · ClinicalTrials.gov registry record · Phase 2
The Effect of Fasudil on Vascular Function in Humans
A Phase 2 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT00120718 is a Phase 2 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 60 participants.
The verdict
NCT00120718, a Phase 2 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate how the rho kinase inhibitor, fasudil, affects vascular function in patients with atherosclerosis and hyperlipidemia.
Interventions
- DRUG fasudil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2002-06 |
| Est. Completion | 2007-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00120718
The ClinicalTrials.gov registry entry for NCT00120718 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which fasudil is the first listed.
NCT00120718 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00120718 about?
NCT00120718 is a clinical study titled "The Effect of Fasudil on Vascular Function in Humans". The purpose of the study is to evaluate how the rho kinase inhibitor, fasudil, affects vascular function in patients with atherosclerosis and hyperlipidemia.
What is the current status of trial NCT00120718?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2002-06. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00120718?
The interventions under investigation include: fasudil (DRUG).
Who is sponsoring clinical trial NCT00120718?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.